X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fulford India with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs AUROBINDO PHARMA - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA AUROBINDO PHARMA FULFORD INDIA/
AUROBINDO PHARMA
 
P/E (TTM) x 398.8 20.8 1,917.2% View Chart
P/BV x 6.2 3.9 159.4% View Chart
Dividend Yield % 0.1 0.3 26.4%  

Financials

 FULFORD INDIA   AUROBINDO PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
AUROBINDO PHARMA
Mar-18
FULFORD INDIA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs942809 116.4%   
Low Rs450504 89.3%   
Sales per share (Unadj.) Rs691.4281.1 246.0%  
Earnings per share (Unadj.) Rs11.541.4 27.7%  
Cash flow per share (Unadj.) Rs15.450.9 30.2%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.30.4 75.5%  
Book value per share (Unadj.) Rs380.0199.4 190.6%  
Shares outstanding (eoy) m3.90585.88 0.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.02.3 43.1%   
Avg P/E ratio x60.715.9 382.5%  
P/CF ratio (eoy) x45.312.9 351.2%  
Price / Book Value ratio x1.83.3 55.6%  
Dividend payout %17.46.0 288.7%   
Avg Mkt Cap Rs m2,714384,630 0.7%   
No. of employees `0000.417.3 2.6%   
Total wages/salary Rs m50521,308 2.4%   
Avg. sales/employee Rs Th6,073.09,500.7 63.9%   
Avg. wages/employee Rs Th1,137.41,229.4 92.5%   
Avg. net profit/employee Rs Th100.71,397.9 7.2%   
INCOME DATA
Net Sales Rs m2,696164,666 1.6%  
Other income Rs m1251,020 12.3%   
Total revenues Rs m2,822165,686 1.7%   
Gross profit Rs m-4637,718 -0.1%  
Depreciation Rs m155,580 0.3%   
Interest Rs m10777 1.2%   
Profit before tax Rs m5432,380 0.2%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m108,183 0.1%   
Profit after tax Rs m4524,229 0.2%  
Gross profit margin %-1.722.9 -7.5%  
Effective tax rate %17.725.3 70.0%   
Net profit margin %1.714.7 11.3%  
BALANCE SHEET DATA
Current assets Rs m1,738121,878 1.4%   
Current liabilities Rs m54586,806 0.6%   
Net working cap to sales %44.321.3 207.8%  
Current ratio x3.21.4 227.3%  
Inventory Days Days48130 37.3%  
Debtors Days Days468 6.3%  
Net fixed assets Rs m1281,037 0.0%   
Share capital Rs m39586 6.7%   
"Free" reserves Rs m1,443116,218 1.2%   
Net worth Rs m1,482116,804 1.3%   
Long term debt Rs m04,512 0.0%   
Total assets Rs m2,077211,052 1.0%  
Interest coverage x6.742.7 15.7%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.8 166.4%   
Return on assets %2.611.8 22.0%  
Return on equity %3.020.7 14.5%  
Return on capital %4.327.4 15.7%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1780,727 0.0%   
Fx outflow Rs m67334,700 1.9%   
Net fx Rs m-65646,027 -1.4%   
CASH FLOW
From Operations Rs m9019,548 0.5%  
From Investments Rs m105-19,570 -0.5%  
From Financial Activity Rs m-148,642 -0.2%  
Net Cashflow Rs m1818,922 2.0%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 8.0 47.8%  
FIIs % 0.1 27.7 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 10.2 207.8%  
Shareholders   4,783 69,601 6.9%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   GLENMARK PHARMA  UNICHEM LAB  WYETH LTD  DIVIS LABORATORIES  ALEMBIC LTD  

Compare FULFORD INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Oct 3, 2018 | Updated on Oct 3, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 8-QTR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS